indazoles has been researched along with cabozantinib in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (73.53) | 24.3611 |
| 2020's | 9 (26.47) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Carver, BS; Doran, MG; Evans, MJ; Sawyers, CL; Spratt, DE; Ulmert, D; Wongvipat, J | 1 |
| Liu, J; Zhang, B; Zhang, X; Zhou, T | 1 |
| Covell, LL; Ganti, AK | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Putora, PM; Rini, B; Rothermundt, C; Schmidinger, M; Sternberg, CN; von Rappard, J | 1 |
| Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
| Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Le Dret, L; Opolon, P; Vassal, G; Vievard, A; Villa, I | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M | 1 |
| Gu, J; Li, J | 1 |
| Dalhaug, A; Nieder, C; Norum, J; Pawinski, A; Syed, MA | 1 |
| Gandhi, S; George, S; Jain, RK | 1 |
| Akaike, K; Hayashi, T; Hosoya, M; Kaneko, K; Kim, Y; Kobayashi, E; Kohsaka, S; Kubota, D; Mogushi, K; Mukaihara, K; Okubo, T; Saito, T; Sato, S; Suehara, Y; Tanabe, Y | 1 |
| 'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ | 1 |
| Ball, MW; Srinivasan, R | 1 |
| Duchesneau, E; Ghate, S; McDonald, E; Messali, A; Perez, JR; Swallow, E | 1 |
| Bhatia, S; Blom, A; Nghiem, P; Olencki, T; Parvathaneni, U; Tarabadkar, ES; Thomas, H | 1 |
| Bodnar, L; Chrom, P; Czarnecka, AM; Kawecki, M; Stec, R; Szczylik, C | 1 |
| Ciccarese, C; Iacovelli, R; Mosillo, C; Tortora, G | 1 |
| Arroyo, A; Choueiri, TK; Dean, M; Escudier, B; Geertsen, PF; George, D; Grande, E; Gross-Goupil, M; Gurney, H; Kollmannsberger, C; Markby, DW; Motzer, RJ; Pal, S; Park, SH; Pikiel, J; Powles, T; Rha, SY; Suarez, C | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Borchiellini, D | 1 |
| Albiges, L; Auclin, E; Auvray, M; Barthelemy, P; Bono, P; De Velasco, G; Escudier, B; Gravis, G; Gross-Goupil, M; Kellokumpu-Lehtinen, P; Mouillet, G; Mourey, L; Powles, T; Priou, F; Rolland, F; Vano, YA | 1 |
| Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M | 1 |
| Bhutani, G; Emamekhoo, H; Kyriakopoulos, CE; Matkowskyj, KA; Zarling, L; Ziemlewicz, T | 1 |
| Feng, C; Li, Y; Shen, Y; Wen, H; Zhu, Z | 1 |
| Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I | 1 |
| Chun, FKH; Deuker, M; Karakiewicz, PI | 1 |
| Armstrong, AJ; Brown, LC; Campbell, MT; Corn, P; Economides, M; Gao, J; Garmezy, B; George, DJ; Gupta, RT; Harrison, MR; Jonasch, E; Kao, C; Kinsey, EN; Laccetti, AL; Msaouel, P; Shah, A; Tannir, N; Venkatesan, A; Xiao, L; Zhang, T; Zurita-Saavedra, A | 1 |
| Aust, D; Folprecht, G; Fröhling, S; Glimm, H; Hanf, D; Heining, C; Herbst, F; Hutter, B; Jahn, A; Laaber, K; Nebelung, H; Richter, D; Uhrig, S | 1 |
| Alfsen, GC; Farkas, L; Geisler, J; Kristensen, VN; Müller, S; Naji, F; Nilsen, FS; Oldenburg, J; Puco, K; Tahiri, A | 1 |
| Banna, GL; Brighi, N; Brunelli, M; Buti, S; Caffo, O; Cattrini, C; Corianò, M; De Giorgi, U; Fornarini, G; Giannarelli, D; Giudice, GC; Kinspergher, S; Malgeri, A; Mennitto, A; Puglisi, S; Rametta, A; Rebuzzi, SE; Roviello, G; Santoni, M; Scartabellati, G; Signori, A; Stellato, M; Tommasi, C; Verzoni, E | 1 |
15 review(s) available for indazoles and cabozantinib
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones | 2017 |
Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Topics: Anilides; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Neoplasms; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib | 2017 |
Kidney cancer in 2017: Challenging and refining treatment paradigms.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Nephrectomy; Nivolumab; Programmed Cell Death 1 Receptor; Pyridines; Pyrimidines; Sulfonamides | 2018 |
Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Anilides; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Middle Aged; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib | 2018 |
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2020 |
Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure.
Topics: Anilides; Axitinib; Carcinoma, Renal Cell; Drug Therapy, Combination; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases | 2020 |
1 trial(s) available for indazoles and cabozantinib
| Article | Year |
|---|---|
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome | 2018 |
18 other study(ies) available for indazoles and cabozantinib
| Article | Year |
|---|---|
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.
Topics: Anilides; Animals; Axitinib; Bone Regeneration; Crizotinib; Fluorine Radioisotopes; Fractures, Bone; Imidazoles; Indazoles; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Radiopharmaceuticals; Technetium Tc 99m Medronate; Tomography, Emission-Computed, Single-Photon | 2014 |
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.
Topics: Algorithms; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Consensus; Decision Support Techniques; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Nivolumab; Protein Kinase Inhibitors; Pyridines; Treatment Failure | 2017 |
Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.
Topics: Anilides; Animals; Apoptosis; Axitinib; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Imidazoles; Indazoles; Mice; Neoplasm Invasiveness; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2017 |
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Rural Population; Sulfonamides; Sunitinib | 2017 |
Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dasatinib; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Sarcoma, Alveolar Soft Part; src-Family Kinases; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis | 2018 |
The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Nivolumab; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.
Topics: Aged; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Skin Neoplasms; Sulfonamides | 2018 |
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Axitinib; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines | 2018 |
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Topics: Adult; Aged; Anilides; Antineoplastic Agents, Immunological; Axitinib; Carcinoma, Renal Cell; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Treatment Failure | 2019 |
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
Topics: Aged; Anilides; Carcinoma, Renal Cell; Cysts; Humans; Indazoles; Kidney Neoplasms; Liver Diseases; Male; Neoplasm Metastasis; Pyridines; Pyrimidines; Sulfonamides | 2020 |
Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
Topics: Anilides; Antineoplastic Agents; Arylsulfotransferase; Axitinib; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Chromogranins; Computer Simulation; Cyclin E; DNA Copy Number Variations; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits, Gs; Humans; Indazoles; Kidney Neoplasms; Oncogene Proteins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib | 2020 |
Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Patient Selection; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib | 2020 |
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; Retrospective Studies; Sulfonamides; Survival Rate; Treatment Outcome | 2021 |
Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With
Topics: Adult; Anilides; Benzamides; Drug Resistance, Neoplasm; ETS Translocation Variant 6 Protein; Gene Fusion; Humans; Indazoles; Male; Mutation; Proto-Oncogene Proteins c-ets; Pyridines; Receptor, trkC; Repressor Proteins; Thyroid Neoplasms; Treatment Outcome | 2021 |
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.
Topics: Anilides; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nerve Growth Factors; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; src-Family Kinases; Sulfonamides; Sunitinib | 2022 |
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |